🟢 Tenax Therapeutics is trading 10.81% up today in pre-market with no confirmed catalyst identified

Tenax Therapeutics is trading at $2.05, +10.81% in pre-market, with no confirmed company-specific catalyst identified.

• No new company-specific announcement was identified for August 25, 2026; Tenax’s latest official release remains the August 10 LEVEL trial update.
• The trial missed its primary endpoint, though exploratory analyses showed a 49% greater reduction in NT-proBNP versus placebo.
• Tenax is scheduled to present LEVEL data at the ESC Congress on August 29, 2026.